Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — ESG Presentation (November 2020)
33 slides from Novo Nordisk A/s Class B's sustainability presentation, Nov 30, 2020
Slide 1: Novo Nordisk - a focused healthcare company, ESG conference call
Novo Nordisk - a focused healthcare company ESG conference call 30 November 2020
Slide 2: Forward-looking statements
2 ESG conference call Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company’s statutory Annual Report 2019 and Form 20-F, which are both expected to be filed with
Slide 3: Strategic Aspirations 2025 with today's focus on Purpose and sustainability
3 ESG conference call Novo Nordisk® Strategic Aspirations 2025 with today’s focus on Purpose and sustainability • Further raise the innovation-bar for diabetes treatment • Being respected for adding value to society • Develop a leading portfolio of superior treatment solutions for obesity • Progress
Slide 4: Building upon extensive experience running a sustainable business
4 ESG conference call Novo Nordisk® Building upon extensive experience running a sustainable business 2014 2018 2020: 100% renewable 2002: electricity across our All Novo Nordisk global production factories ISO 2000: 14001 certified 2011 The Novo 2005 Nordisk way of Launch of the 2005: Novo Nordisk
Slide 5: Long-term value to society is driven by a strong sense of purpose and by being a responsible business
5 ESG conference call Novo Nordisk® Long-term value to society is driven by a strong sense of purpose and by being a responsible business Foundation ownership allows for long-term strategies, while Financial, environmental and social responsibility anchored still supporting agile responses to changi
Slide 6: Decisions and actions are informed by evaluating where the largest impact can be obtained
6 ESG conference call Novo Nordisk® Decisions and actions are informed by evaluating where the largest impact can be obtained and guided by external standards Our approach Socially to ESG is our responsible The approach is informed by external standards, Acknowledgement of approach is reflected Trip
Slide 7: Agenda
7 ESG conference call Novo Nordisk® Agenda Environmental responsibility – Circular for Zero • Camilla Sylvest, EVP of Commercial Strategy & Corporate Affairs • Henrik Wulff, EVP of Product Supply, Quality and IT E Followed by 10 minutes Q&A on environmental responsibility Social responsibility – Def
Slide 8: With Circular for Zero, Novo Nordisk aspires to have zero environmental impact
8 ESG conference call Novo Nordisk® With Circular for Zero, Novo Nordisk aspires to have zero environmental impact Environmental aspirations Circular products Upgrade existing and design new products based on circular principles and solve the end-of-life product waste challenge to close the resource
Slide 9: Circular mindset implemented in design of devices and in solving end-of-life challenge for products
9 ESG conference call Novo Nordisk® Circular mindset implemented in design of devices and in solving end-of-life challenge for products Circularity in designing products Collect learnings to solve end-of-life waste challenge Today’s challenge: Product offerings within pharma have a Today’s challenge
Slide 10: Optimisations support and enable investments in sustainable production
10 ESG conference call Novo Nordisk® Optimisations support and enable investments in sustainable production Novo Nordisk sales and consumption Investing in sustainable production facilities is development in production key to drive efficiencies and competitive financial results Index Sales CO2 Energ
Slide 11: Progressing towards zero CO2 emissions by addressing emissions in and beyond production
11 ESG conference call Novo Nordisk® Progressing towards zero CO2 emissions by addressing emissions in and beyond production Mapping CO2 emissions is the Addressing the ~20% CO2 emissions Activities to meet zero CO2 from operations first step in finding solutions in operations & transport and transp
Slide 12: Ambition is to have all direct suppliers using 100% renewable power by 2030
12 ESG conference call Novo Nordisk® Ambition is to have all direct suppliers using 100% renewable power when supplying Novo Nordisk by 2030 Driving change with suppliers start with Tier 1 suppliers totals ~60,000 and Actions required to meet 2030 assessing the largest direct impact accounts for ~30
Slide 13: Environment - key take-aways
13 ESG conference call Novo Nordisk® • Design products for circularity Environment - key take-aways • Learn from take-back programme how to solve end-of-life challenge • Aim is for zero CO2 from operations & transportation by 2030 • Ambition is to have all direct suppliers using 100% renewable power
Slide 14: Agenda
14 ESG conference call Novo Nordisk® Agenda Environmental responsibility – Circular for Zero • Camilla Sylvest, EVP of Commercial Strategy & Corporate Affairs • Henrik Wulff, EVP of Product Supply, Quality and IT E Followed by 10 minutes Q&A on environmental responsibility Social responsibility – De
Slide 15: We are driving change to Defeat Diabetes by…
15 ESG conference call Novo Nordisk® We are driving change to Defeat Diabetes by… …accelerating …providing access to …innovating to prevention to affordable care for vulnerable improve lives… bend the curve… patients in every country… … and thereby help society rise to one of its biggest challenges
Slide 16: Innovation is a core element to improve millions of people's lives
16 ESG conference call Novo Nordisk® Innovation is a core element to improve millions of people’s lives Keep people at high risk from Explore transformative treatments for Strive for curative therapies developing diabetes people living with diabetes also within type 1 diabetes % NOT EXHAUSTIVE 0 Inc
Slide 17: Providing access to affordable care for vulnerable patients in every country
17 ESG conference call Novo Nordisk® Providing access to affordable care for vulnerable patients in every country Finding solutions to improve care for vulnerable patients in every Partnerships are essential to country requires a multi-faceted approach and actions reach vulnerable patients Identifyi
Slide 18: US insulin net prices have declined, but vulnerable patients rely on affordability offerings
18 ESG conference call Novo Nordisk® US insulin net prices have declined in recent years, but vulnerable patients rely on our affordability offerings The US population by health Net price development for Novo Nordisk insulin affordability insurance coverage NovoLog® vial offerings in the US Private
Slide 19: Defeating diabetes starts by taking preventive measures
19 ESG conference call Novo Nordisk® Defeating diabetes starts by taking preventive measures Global obesity burden is part of the cause for rising Strengthen prevention by focusing diabetes prevalence for both adults and children on health inequality in cities The global obesity Bend the global obes
Slide 20: The Novo Nordisk Way sets direction for a purpose-driven culture
20 ESG conference call Novo Nordisk® The Novo Nordisk Way sets direction for a purpose-driven culture The Novo Nordisk Way describes who we are, where we want to go and the values that characterise our company1 • We aim to lead in all disease areas in which we are active • Our key contribution is to
Slide 21: The aspiration is to be a sustainable workplace
21 ESG conference call Novo Nordisk® The aspiration is to be a sustainable workplace Organise to win by accelerating Grow our people and be a Drive cultural evolution to be diversity and inclusion talent incubator an employer for the future Aspiring for balanced gender An organisation that An organi
Slide 22: Diversity and inclusion is a key focus area for Novo Nordisk
22 ESG conference call Novo Nordisk® Diversity and inclusion is a key focus area for Novo Nordisk Novo Nordisk is committed to building Driving an inclusive and diverse workplace a diverse and inclusive culture • Aspiring for balanced gender representation at all managerial levels All managers Sr. M
Slide 23: A purpose driven culture is supported by facilitation to safeguard Novo Nordisk values
23 ESG conference call Novo Nordisk® A purpose driven culture is supported by facilitation to safeguard Novo Nordisk values Facilitation purpose Facilitations – Ensure we walk the talk • A systematic approach to follow up on how the Novo Nordisk Way is embedded in the organisation Safeguarding • Fac
Slide 24: Social responsibility - key take-aways
24 ESG conference call Novo Nordisk® Social responsibility - key take-aways • Defeat Diabetes • Accelerating prevention to bend the curve • Providing access to affordable care for vulnerable patients in every country • Innovating to improve lives • Ensure a sustainable workplace by ensuring • A dive
Slide 25: Agenda
25 ESG conference call Novo Nordisk® Agenda Environmental responsibility – Circular for Zero • Camilla Sylvest, EVP of Commercial Strategy & Corporate Affairs • Henrik Wulff, EVP of Product Supply, Quality and IT E Followed by 10 minutes Q&A on environmental responsibility Social responsibility – De
Slide 26: Structure in place to ensure corporate governance
26 ESG conference call Novo Nordisk® Structure in place to ensure corporate governance Rules and Regulations Governance structure Assurance measures Shareholders A and B share structure Danish and foreign laws and Audit financial data and review regulations social and environmental data Board of Dir
Slide 27: Robust governance in place to ensure responsible business principles translate into conduct
27 ESG conference call Novo Nordisk® Robust governance in place to ensure responsible business principles translate into conduct • UN Guiding Principles on Business and Human Rights International standards and principles • OECD Guidelines for multi-national enterprises for responsible business condu
Slide 28: Global Business Ethics Code of Conduct based on the Novo Nordisk Way
28 ESG conference call Novo Nordisk® Global Business Ethics Code of Conduct based on the Novo Nordisk Way Novo Nordisk Way Business ethics compliance framework “We never compromise on quality and business ethics” Identify • Trends such as increased focus on anti-bribery and anti-corruption legislati
Slide 29: Novo Nordisk has a sustainable tax approach
29 ESG conference call Novo Nordisk® Novo Nordisk has a sustainable tax approach • Business structures driven by commercial considerations Commercially • Pay taxes where value is generated driven • Effective tax rate of 20 – 22% for 2020 Sustainable • No artificial structures or tax havens tax Respo
Slide 30: Short- and long-term incentive programmes have links to Strategic Aspirations 2025
30 ESG conference call Novo Nordisk® Both short- and long-term incentive programmes have links to Strategic Aspirations 2025 Remuneration policy Strategic aspirations 2025 Remuneration report Purpose and Innovation and sustainability therapeutic focus Commercial execution Financials Remuneration pol
Slide 31: Progress reporting on sustainability in Integrated Annual Report
31 ESG conference call Novo Nordisk® Progress reporting on sustainability in Integrated Annual Report • Energy consumption for operations • Share of renewable power for production sites Environmental statement • Water consumption for production sites • CO2 emissions from operations and transportatio
Slide 32: Governance - key take-aways
32 ESG conference call Novo Nordisk® Governance - key take-aways • Clearly defined governance structure, compliance and assurance • Sustainability approach defined and integrated • Integrated reporting approach since 2004
Slide 33: Thank you for today
Thank you for today For more information on the material presented today including detailed reporting, please see our website novonordisk.com